1. Impact of antibiotic restrictions: the pharmaceutical perspective
E. Power 
Clinical Microbiology and Infection 
Volume 12, Pages (August 2006)
DOI: /j x
Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
The relationship between net present value (NPV) and the potential for successful pharmaceutical registration, and the impact of antibiotic restrictions and increased regulatory hurdles.
Clinical Microbiology and Infection  , 25-34DOI: ( /j x)
Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
In terms of net present value (NPV), maintaining antibiotic efficacy is in the interests of pharmaceutical companies.
Clinical Microbiology and Infection  , 25-34DOI: ( /j x)
Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3
Antibiotic restrictions are being placed at many levels throughout the healthcare management structure.
Clinical Microbiology and Infection  , 25-34DOI: ( /j x)
Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

5. Fig. 4
Antibiotic restrictions lead to decreased innovation and investment in antibiotic research and development (R&D).
Clinical Microbiology and Infection  , 25-34DOI: ( /j x)
Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions